In addition to AML, CD123 has been implicated in other myeloid malignancies such as Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), and Chronic Myeloid Leukemia (CML), and blastic plasmacytoid dendritic cell neoplasm (BPDCN) (76). Here, IL3RA is linked to CD4+/CD56+ hematodermic neoplasm.